BuddyBoy suggested: "When Leronlimab gets approved for inflammation, it should be stocked in every single Emergency facility. Just my opinion, but, a very realistic scenario."
The use of leronlimab in emergent situations like overwhelming sepsis due to cytokine storm, Acute CVA (stroke) or most any head trauma, thyroid storm, graft vs host hypotension, etc. etc. etc. will become standard of care. The list will be large.
More important will be the price point that management sets for leronlimab. There will be a huge market for the sub-acute or chronic use of leronlimab in everyday medicine. Keeping leronlimab affordable especially for the myriad conditions that befall the geriatric population will be important.
It is time to show big pharma and the cynical world that a blockbuster drug does not need to hugely expensive.
CYDY will make a lot of money on volume, not price gouging measured by billions with a drug that will also be important to billions!